MedTrace Logo

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

NCT00162305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-10-27

No results posted yet for this study

Summary

The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

BMS-512148

Capsules, Oral, 100 mg, Once daily, 14 days.

DRUG

BMS-512148

Capsules, Oral, 25 mg, Once daily, 14 days.

DRUG

BMS-512148

Capsules, Oral, 5 mg, Once daily, 14 days.

DRUG

Placebo

Capsules, Oral, 0 mg, Once daily, 14 days.

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162305 on ClinicalTrials.gov